Search PubMed⌕ Search

Biomedical subjects

H Borberg

Publications and source records attributed to H Borberg.

At least 91 records · Page 5Linked to original sources
PubMed1979

Plasma separation in Goodpasture's syndrome and multiple myeloma.

1. Plasma separation using membranes is equally as effective as plasmapheresis using a cell separator. 2. In Goodpasture's syndrome pulmonary haemorrhage improves very quickly with plasma separation. In patients with multiple myeloma, hyperproteinaemia is easy to correct. 3. Plasma separation is well tolerated, both subjectively by the patient and objectively by the circulation. 4. Since the membranes are permeable not only to IgG but also to IgM, circulating antigen-antibody-complement complexes must also be easy to remove using the plasma separation method.

Adolescent↗
PubMed1978

[Graft-versus-host reaction following granulocyte transfusion from a normal donor (author's transl)].

Graft-versus-Host disease following the transfusion of leukocytes from normal donor occured during remission-reinduction therapy in a 5 years old girl with acute lymphocytic leukemia. The clinical picture consisting of rash, diarrhea and somnolence was congruent with the diagnosis. Graft-versus-Host disease was confirmed by histology of skin biopsy and exclusion of other causes. The child survived the disease. We recommend the irradiation of leukocyte concentrates before transfusion.

Biopsy↗
PubMed1977

The utilization of a new strength citrate anticoagulant during centrifugal plateletpheresis. II. Assessment of in vitro platelet function.

Platelets contained in concentrates prepared by intermittent flow centrifugation utilizing 5.0 g total ionized citrate, function normally as assessed by tests for adhesion, spreading, and ADP and collagen-induced aggregation. The ability of platelets to adhere and to aggregate following incubation with ADP is significantly reduced, in samples taken immediately after the collection procedure. Total platelet collection and platelet collection efficiency, is not compromised by use of the above citrate concentration.

Anticoagulants↗
PubMed1977

Hydroxyethyl starch. An agent for hypovolaemic schock treatment II. Urinary excretion in normal volunteers following three consecutive daily infusions.

1 Urinary hydroxyethyl starch (HES) concentrations were determined by the anthrone method, in four healthy normal male volunteers following three consecutive daily 500 ml infusions (total 1500 ml), in order to ascertain excretion rates under normal controlled conditions. 2 The HES was excreted at a rate of 2.57, 2.46, and 2.44 g/h during the first hour postinjection, on days 1, 2, and 3, respectively. 3 The rate during the interval 12-24 h postinjection, averaged 0.14, 0.21, and 0.10 g/h, on days 1,2, and 3, respectively. 4 In the intervals 24-72, 72-120, and 120-168 h after the third and final injection, the excretion rate was 0.07, 0.04, and 0.02 g/h, respectively. 5 Renal function, as assessed by serum creatinine and uric acid concentrations and 24 h void volumes, was normal during the entire period of observation. 6 The results indicate that HES is excreted at a similar rate following three consecutive daily infusions without evidence of renal injury.

Adult↗
PubMed1975

[Results of the synchronization therapy with vincristine and cyclophosphamide in lymphogranulomatosis, reticulum cell sarcoma and lymphosarcoma. A phase II study (author's transl)].

The effectiveness of synchronization therapy was tested on 88 patients who had already undergone some form of treatment for lymphogranulomatosis (stage III B and IV), generalized reticulum cell sarcoma or lymphosarcoma. This therapeutical concept is based on a partial synchronic increase in tumor cells induced by noncytocidal doses of vincristine, followed by cytostatic or cytocidal treatment with cyclophosphamide during DNA synthesis of the partially synchronized tumor cells. The therapeutic plan is similar to a single-agent therapy. In lymphogranulomatosis, complete remission could be achieved in 14 out of 19 cases (stage III B) and in 9 out of 24 cases (stage IV). The mean remission period during an orally administered cytostatic maintenance therapy was 15 1/2 months. The highest rate of remission was found in the mixed cell type of granulomas (23 out of 24 patients). In the non-Hodgkin's lymphomas, complete remission was achieved in 13 out of 30 cases (lymphosarcoma) and in 19 out of 15 cases (reticulum cell sarcoma). The mean remission period for orally administered cytostatic maintenance therapy was 16 months for lymphosarcoma and 11 1/2 months for reticulum cell sarcoma. These therapeutic results are comparable to those achieved by very effective schemes of combination chemotherapy but the toxic side-effects of synchronization therapy are considerably lower.

Adolescent↗